Drug Trial Radar · NCT01072929
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Last checked: Nov 20, 2026Latest source record: Apr 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
433
Actual
Start
Jan 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- Feb 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.
Conditions
- Depression
Interventions
ArmodafinilDrug
Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
PlaceboDrug
Matching Placebo, also in tablet form taken orally, once daily in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)Time frame: Day 0 (baseline), Week 8
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Birmingham Research Group
Birmingham, Alabama
Southwestern Research
Beverly Hills, California
Collaborative NeuroScience Network
Garden Grove, California
Sun Valley Behavioral Medical
Imperial, California
University of California Irvine
Irvine, California
Excell Research
Oceanside, California
Artemis Institute for Clinical Research
San Diego, California
Clinical Innovations Inc.
Santa Ana, California
Viking Clinical Research Center
Temecula, California
CNS Clinical Research Group - Florida Clinical Research Cent
Coral Springs, Florida
Gulfcoast Clinical Research Center
Fort Myers, Florida
Sarkis Clinical Trials
Gainesville, Florida
Dr. Vijapura and Assoc.
Jacksonville, Florida
Fidelity Clinical Research
Lauderhill, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
University of South Florida
Tampa, Florida
Comprehensive Neuroscience, Inc
Atlanta, Georgia
Northwest Behavioral Research Center
Roswell, Georgia
AMR Baber Research Inc.
Naperville, Illinois
American Medical Research
Oak Brook, Illinois
CNS - Comprehensive Neuro Science
Park Ridge, Illinois
Pharmasite Research, Inc
Baltimore, Maryland
AccelRx Research
Fall River, Massachusetts
Mid-America Clinical Research, LLC
St Louis, Missouri
CRI Worldwide, LLC
Mount Laurel, New Jersey
Albequerque Neuroscience
Albuquerque, New Mexico
Social Psychiatry Research Institute
Brooklyn, New York
Eastside Comprehensive Medical Center
New York, New York
Finger Lakes Clinical Research
Rochester, New York
Richmond Behavioral Associates
Staten Island, New York
Richard Weisler, MD and Associates
Raleigh, North Carolina
Charak Clinical Research Center
Beachwood, Ohio
Midwest Clinical Research Center
Dayton, Ohio
Oregon Center for Clinical Investigations, Inc
Salem, Oregon
Suburban Research Associates
Media, Pennsylvania
Scranton Counseling Center
Scranton, Pennsylvania
Carolina Clinical Trials, Inc.
Charleston, South Carolina
Community Clinical Research
Austin, Texas
FutureSearch Trials of Neurology
Austin, Texas
Northwest Clinical Research Center
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.